Search results for "Definitive chemoradiotherapy"

showing 2 items of 2 documents

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and sa…

2020

Abstract Background Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy and safety. Methods Data from 56 centres were analysed for adverse events (AE), progression-free survival (PFS), overall survival (OS). Results 126 patients actually received at least 1 cycle durvalumab. Compared to the PACIFIC trial, the EAP population had more advanced stage and included “oligometastatic” stage IV patients and patients with autoimmune disease. PFS (20.1 mont…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsDurvalumabPopulationLocally advancednon-small cell lung cancer (NSCLC)03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicinemedicineHumanseducationAdverse effecteducation.field_of_studybusiness.industryAntibodies MonoclonalChemoradiotherapyDefinitive chemoradiotherapymedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisExpanded accessbusinessChemoradiotherapyLung Cancer
researchProduct

P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma recei…

2020

medicine.medical_specialtybusiness.industryHematologyDefinitive chemoradiotherapyPembrolizumabPlacebomedicine.diseaseGastroenterologyDouble blindOncologyInternal medicineCarcinomaMedicineIn patientbusinessAnnals of Oncology
researchProduct